

Reference: FOI 30439 BUCKS 14Y

Subject: Cannabis Based Medical Products

I can confirm that the CCG does hold some of information requested; please see responses below:

QUESTION	RESPONSE
<p>1. Please state the unlicensed cannabis based medical products you have approved for prescription by consultants (on the General Medical Council’s specialist register), in your Care Commissioning Group’s area on an NHS prescription to their patients. ('Unlicensed' refers to the medicine not having received Market Approval in the UK by the Medicines and Healthcare products Regulatory Agency and it not being listed in Schedule 4 of the Misuse of Drugs Regulations 2001).</p>	<p>There is not anything on the formulary; however, there is a holding statement pending NICE recommendation due later this year. There is a process by which an unlicensed use can be requested and this would be through the IFR process.</p>
<p>2. Please state the number of prescriptions that have been issued for the following cannabis based medical products since 01/11/2018:</p> <ul style="list-style-type: none"> - Nabiximols (Sativex). Product code: PL 18024/0009. - Cannabidiol (Epidiolex). Product code: N/A. 	<p>None.</p>



Buckinghamshire
Clinical Commissioning Group

The information provided in this response is accurate as of 18 April 2019, and has been authorised for release by Robert Majilton, Deputy Chief Officer and Director of Sustainability & Transformation for NHS Buckinghamshire CCG.